No Abstract BioWorld International CorrespondentCevec Pharmaceuticals GmbH raised €4 million (US$5.9 million) in new funding to support the commercialization of its proprietary protein expression platform CAP, which the company is positioning as a high-yield technology for the production of complex proteins.
